Abstracts tagged "Vasculitis"

Abstract Number: 2229 • ACR Convergence 2022
Ultrasound Localization Microscopy as a New Tool for Takayasu’s Arteritis Activity Assessment, a Deep Insight Within Carotid Wall Inflammation
Guillaume Goudot¹, Anatole Jimenez², Nassim Mohamedi³, jonas Sitruk³, Lina Khider¹, Hélène Mortelette³, Clément Papadacci², Fabien Hyafil⁴, Mickaël Tanter², Emmanuel Messas¹, Mathieu Pernot² and Tristan Mirault¹, ¹Vascular medicine department, Georges Pompidou European hospital, APHP, Université Paris Cité, INSERM U970 PARCC, Paris, Ile-de-France, France, ²Physics for Medicine Paris, INSERM U1273, ESPCI Paris, CNRS FRE 2031, PSL Research University, Paris, France, ³Vascular medicine department, Georges Pompidou European hospital, APHP, Université Paris Cité, Paris, Ile-de-France, France, ⁴Nuclear medicine department, Georges Pompidou European hospital, APHP, Universite Paris Cite, INSERM U970 PARCC, Paris, Ile-de-France, France
Background/Purpose: Use of sulphur hexafluoride microbubbles (MB) with ultrasound allow to assess arterial wall vascularization through signal enhancement. The use of ultrafast imaging with MB…
Abstract Number: 0460 • ACR Convergence 2022
Baseline Glucocorticoid Toxicity in the Treatment of Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
Naomi Patel¹, Xiaoqing Fu², yuqing zhang³ and John Stone⁴, ¹Massachusetts General Hospital, Sale Creek, TN, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Quincy, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Giant cell arteritis (GCA) requires treatment with high-dose, long-term glucocorticoids (GCs). The development of future GC toxicities may be predicted by baseline toxicities. Thus,…
Abstract Number: 0485 • ACR Convergence 2022
Assessing the Effectiveness of Tocilizumab in Newly Diagnosed Giant Cell Arteritis versus Refractory/recurrent Giant Cell Arteritis in Clinical Practice
Julio Sánchez-Martín¹, Javier Loricera², Clara Moriano³, Santos Castañeda⁴, F. Javier Narváez⁵, Vicente Aldasoro⁶, Olga Maiz⁷, Rafael Melero⁸, Juan Ignacio Villa Blanco⁹, Paloma Vela-Casasempere¹⁰, Susana Romero Yuste¹¹, José Luis Callejas¹², Eugenio De Miguel¹³, Eva Galíndez-Agirregoikoa¹⁴, Francisca Sivera¹⁵, Jesus Fernandez¹⁶, Carles Galisteo¹⁷, Ivan Ferraz Amaro¹⁸, Lara Sánchez-Bilbao¹, Monica Calderon-Goercke¹⁹, Miguel Ángel González-Gay²⁰ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁵Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷Hospital Universitario de Donostia, San Sebastián, Spain, ⁸Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ⁹Sierrallana Hospital, Torrelavega, Spain, ¹⁰Hospital General Universitario Alicante, Alicante, Spain, ¹¹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹²Hospital San Cecilio, Granada, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Basurto University Hospital, Bilbao, Spain, ¹⁵Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁶Hospital de La Coruña, La Coruña, Spain, ¹⁷Hospital Parc Tauli,, Sabadel, Spain, ¹⁸Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ¹⁹Hospital de Sierrallana, Torrelavega, Spain, ²⁰Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Tocilizumab (TCZ) is the only biologic drug approved in giant cell arteritis (GCA), based in two clinical trials (CT) (1,2). CT included selected patients…
Abstract Number: 1072 • ACR Convergence 2022
Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granulomatosis with Polyangiitis (GPA)
Adil Vural¹, Komal Mushtaq¹, Chao Zhang¹, Mahmoud Alwakeel¹, Vickie Sayles¹, Kristine Duly², Carol Langford¹ and Rula Hajj-Ali³, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Fairview Park, OH, ³Cleveland Clinic, Hunting Valley, OH
Background/Purpose: A biosimilar is a medication that is highly similar to a biologic agent that is already approved by a regulatory organization. Considering the share…
Abstract Number: 1550 • ACR Convergence 2022
Involvement of Iliofemoral Arteries in PET/CT Are Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis
SEMA KAYMAZ-TAHRA¹, Salih Ozguven², Nuh Filizoglu², Ali Ugur Unal³, Fatma Alibaz-Oner⁴, Tunc Ones², Tanju Yusuf Erdil² and Haner Direskeneli⁵, ¹Sancaktepe Prof Dr Ilhan Varank Training and Research Hospital, Rheumatology, Istanbul, Turkey, ²Marmara University School of Medicine, Department of Nuclear Medicine, Istanbul, Turkey, ³Marmara University School of Medicine, Rheumatology, Istanbul, Turkey, ⁴Marmara University, Rheumatology, Istanbul, Turkey, ⁵Marmara University, Rheumatology, Istanbul, Istanbul, Turkey
Background/Purpose: Iliofemoral artery disease, which is commonly observed in severe atherosclerosis, may also be present in Takayasu's arteritis (TAK). In this study we aimed to…
Abstract Number: 1574 • ACR Convergence 2022
Vasculitides as Medication-Associated Adverse Events Based on a National Database Reporting System
Alicia Rodriguez-Pla, Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Vasculitides have been reported as adverse events (AEs) related to a wide variety of medications. We aimed to analyze the vasculitides reported to a…
Abstract Number: 2230 • ACR Convergence 2022
Ultra-Rare Genetic Variation in Relapsing Polychondritis: A Whole-Exome Sequencing Study
Yiming Luo¹, Marcela Ferrada¹, Keith Sikora², Daniel Kastner³, Zuoming Deng⁴, Mengqi Zhang⁵, Hugh Alessi¹, Virginia Kraus⁶, Andrew Allen⁶ and Peter Grayson⁷, ¹National Institutes of Health, Bethesda, MD, ²National Institutes of Health Clinical Center, Bethesda, MD, ³National Human Genome Research Institute, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Duke University, Durham, NC, ⁷National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare rheumatic disease of unknown etiology characterized by inflammations of cartilaginous structures and other tissues, particularly the ears, nose,…
Abstract Number: 0462 • ACR Convergence 2022
Increasing Incidence of Large Artery Manifestations in Patients with Giant Cell Arteritis, a Population-based Cohort over 70 Years
Mohanad Elfishawi¹, Mahmut Kaymakci², Sara Achenbach³, Cynthia Crowson⁴, Tanaz Kermani⁵, Cornelia Weyand⁴, Matthew J. Koster¹ and Kenneth J. Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Rochester, MN, Rochester, MN, ⁴Mayo Clinic, Eyota, MN, ⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: Screening for large artery manifestations has been adopted by clinicians managing patients with Giant Cell Arteritis (GCA). The contemporary effect of the increased use…
Abstract Number: 0487 • ACR Convergence 2022
A Systematic Literature Review to Generate Descriptors for the Development of New Response Criteria in Giant Cell Arteritis
Catalina Sanchez Alvarez¹, Milena Bond², Medha Soowamber³, Dario Camellino⁴, Zahi Touma⁵, Sofia Ramiro⁶, Melanie Anderson⁷, Carol Langford⁸ and Christian Dejaco⁹, ¹University of Florida, Gainesville, FL, ²Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ³Mount Sinai Hospital, Woodbridge, ON, Canada, ⁴Azienda Sanitaria Locale 3 Genoa, Genoa, Italy, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷University Health Network, Toronto, ON, Canada, ⁸Cleveland Clinic, Cleveland, OH, ⁹Azienda Sanitaria Alto Adige, Brunico, Italy
Background/Purpose: Giant cell arteritis (GCA) is the most common form of large vessel vasculitis. While remission and relapse are common primary endpoints in clinical trials,…
Abstract Number: 1075 • ACR Convergence 2022
Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype
Benjamin Terrier¹, David Jayne², Bernhard Hellmich³, Jane Bentley⁴, Jonathan Steinfeld⁵, Steven Yancey⁶, Namhee Kwon⁷, Praveen Akuthota⁸, Paneez Khoury⁹, Lee Baylis¹⁰ and Michael Wechsler¹¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²University of Cambridge, Cambridge, United Kingdom, ³Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, ⁴Clinical Statistics, GlaxoSmithKline, Brentford, United Kingdom, ⁵Clinical Sciences, Respiratory, GSK (affiliation at time of research), Philadelphia, PA, ⁶Respiratory Therapeutic Area, GSK (affiliation at the time of research), Research Triangle Park, NC, ⁷Clinical Sciences, Respiratory, GSK, Brentford, United Kingdom, ⁸Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California, San Diego, CA, ⁹Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ¹⁰Global Medical Affairs, GlaxoSmithKline, Durham, NC, ¹¹Department of Medicine, National Jewish Health, Denver, CO
Background/Purpose: Patients with eosinophilic granulomatosis with polyangiitis (EGPA) can have vasculitic or eosinophilic phenotypes. The MIRRA study demonstrated that patients with EGPA spent more time…
Abstract Number: 1551 • ACR Convergence 2022
The Utility of Imaging Studies (MRA and CTA) in Long-Term Monitoring for Patients with Takayasu Arteritis
Saja Almaaitah¹, Chao Zhang² and alexandra villa forte¹, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Takayasu Arteritis (TA) is a complex large vessel vasculitis that leads to arterial stenosis, occlusion and aneurysmal formation. Assessment of disease activity is a…
Abstract Number: 1575 • ACR Convergence 2022
Characteristics of an Internet-Based, International Cohort of Patients with a Self-Reported Diagnosis of Urticarial Vasculitis
Jason Springer¹, Tanaz Kermani², Dianne Shaw³, Kalen Larson⁴, Cristina Burroughs⁵ and Peter Merkel⁶, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of California Los Angeles, Los Angeles, CA, ³Vasculitis Foundation, Chapel Hill, NC, ⁴Vasculitis Foundation, Kansas City, MO, ⁵University of South Florida, Tampa, FL, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Urticarial vasculitis is a markedly rare disease, with an annual incidence of < 1 per million. Hypocomplementemia is associated with systemic features and a…
Abstract Number: 2232 • ACR Convergence 2022
Clinical Features and Long-term Outcomes of Patients with Systemic Polyarteritis Nodosa Diagnosed Since 2005: Data from 196 Patients
Julien ROHMER¹, ludovic trefond², Yann Nguyen³, Christian Agard⁴, Jean Sebastien ALLAIN⁵, Alice Berezne⁶, Pierre Charles⁷, Pascal Cohen⁸, guillaume gondran⁹, Matthieu GROH¹⁰, Tessa HUSCENOT¹¹, carole lacout¹², Estibaliz Lazaro¹³, Jonathan London¹⁴, Francois Maurier¹⁵, Arsene Mekinian¹⁶, Isabelle Nubourgh¹⁷, Rafik MESBAH¹⁸, Xavier Puéchal⁸, Laurent Perard¹⁹, Mathieu Puyade²⁰, Gregory Pugnet²¹, Viviane Queyrel²², Diane Rouzaud²³, Arthur Roux²⁴, Cecile-Audrey DUREL¹⁹, Loïc Guillevin⁸ and Benjamin Terrier⁸, ¹APHP, Suresnes, France, ²Chu clermont ferrand, Clermont-Ferrand, France, ³AP-HP.Centre Universit Paris Cit Hôpital Cochin, Montmorency, France, ⁴Internal medicine, Nantes University Hospital, Nantes, France, ⁵CHU rennes, Rennes, ⁶CH Annecy, Annecy, France, ⁷Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, ⁸National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁹CHU limoges, Limoges, France, ¹⁰Foch Hospital, Suresnes, France, ¹¹APHP, Boulogne, France, ¹²CHU Angers, Angers, France, ¹³Bordeaux Hospital University, Bordeaux, France, ¹⁴Hôpital Croix-Saint-Simon, Paris, France, ¹⁵Hôpitaux privés de Metz, Metz, France, ¹⁶AP-HP, Hopital Saint Antoine, Paris, France, ¹⁷Ch St Pierre, Brussels, Belgium, ¹⁸Boulogne Ch, Boulogne, France, ¹⁹CHU Lyon, Lyon, France, ²⁰Centre Hospitalier Universitaire de Poitiers, Poitiers, France, ²¹CHU Toulouse Purpan Service de Medecine Interne, Toulouse, France, ²²CHU NIce, Nice, France, ²³Bichat, Paris, France, ²⁴MGEN, Paris, France
Background/Purpose: The etiological landscape of systemic polyarteritis nodosa (PAN) has substantially changed since the onset of hepatitis B virus (HBV) vaccination and the discovery of…
Abstract Number: 0038 • ACR Convergence 2022
STING Antagonist (IFM4490) Inhibits STING Activation and STING Dependent Signal Transduction in Patients with STING-associated Vasculopathy with Onset in Infancy (SAVI)
Sachin Gaurav¹, Bin Lin², Sophia Park³, Shankar Venkatraman⁴, David Winkler⁴ and Raphaela Goldbach-Mansky⁵, ¹Translational Autoinflammatory Diseases Section, LCIM, NIAID,, Bethesda, MD, ²NIH, Bethesda, MD, ³NIAID, Bethesda, MD, ⁴IFM Therapeutics, Boston, MA, ⁵NIH/NIAID, Potomac, MD
Background/Purpose: SAVI is a rare, autoinflammatory type I interferonopathy caused by gain-of-function mutations that cause STING activation and excessive production of type I interferons and…
Abstract Number: 0463 • ACR Convergence 2022
Utilization of a Giant Cell Arteritis Fast-Track Program Independent of Ultrasound at a Single Center
Christina Costeas, Shubhasree Banerjee, Madhura Tamhankar, Naomi Amudala, Peter Merkel and Rennie Rhee, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Giant Cell Arteritis (GCA) Fast-Track program was implemented at our center with the goal of accelerating diagnosis of this rare and rapidly progressive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].